Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03441581 · ClinicalTrials.gov registry record · Phase 4
Eluxadoline Bile Acid Malabsorption (BAM) Study
A Phase 4 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
NCT03441581 is a Phase 4 study that has completed, run by Allergan. The registered enrollment target is 24 participants.
The verdict
NCT03441581, a Phase 4 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study will evaluate the possibility of a differential effect of eluxadoline on altered bowel function in Irritable Bowel Syndrome with Diarrhea (IBS-D) participants with and without evidence of Bile Acid Malabsorption (BAM).
Interventions
- DRUG Eluxadoline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2018-02-23 |
| Est. Completion | 2020-04-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03441581
The ClinicalTrials.gov registry entry for NCT03441581 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Eluxadoline is the first listed.
NCT03441581 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03441581 about?
NCT03441581 is a clinical study titled "Eluxadoline Bile Acid Malabsorption (BAM) Study". This study will evaluate the possibility of a differential effect of eluxadoline on altered bowel function in Irritable Bowel Syndrome with Diarrhea (IBS-D) participants with and without evidence of Bile Acid Malabsorption (BAM).
What is the current status of trial NCT03441581?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2018-02-23. Estimated completion is 2020-04-28.
What interventions are being tested in trial NCT03441581?
The interventions under investigation include: Eluxadoline (DRUG).
Who is sponsoring clinical trial NCT03441581?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.